Immunologiske herpes simplex-virusantigener og fremgangsmåte for anvendelse derav

摘要

A pharmaceutical composition comprising (1) a herpes simplex virus (HSV) U L 19 protein or a variant thereof exhibiting at least 70% identity therewith, and which elicits a cellular immune response to HSV-2; or a fusion protein comprising the U L 19 protein or variant and an unrelated sequence, or comprising multiple HSV polypeptides; and (2) a pharmaceutically acceptable carrier.